卡瑞利珠单抗联合化疗与单纯化疗治疗III、IV期NSCLC疗效的Meta分析

Meta-Analysis of the Efficacy of Combined Camrelizumab and Chemotherapy versus Monotherapy with Chemotherapy in the Treatment of Stage III and IV Non-Small Cell Lung Cancer (NSCLC)

摘要: 目的：运用Meta分析方法系统评价卡瑞利珠单抗联合化疗治疗III、IV期非小细胞肺癌(NSCLC)的疗效及安全性。方法：检索CNKI、万方、中国生物医学文献服务系统、Pubmed，提取数据并进行核对，利用RevMan5.4软件Cochrane偏倚风险工具，对随机对照试验进行风险评估，并应用该软件进行Meta分析。结果：共纳入7个随机对照试验，包括463例患者。Meta分析结果显示：卡瑞利珠单抗联合化疗在客观缓解率[OR = 3.04, 95%CI (1.90, 4.85), P < 0.00001]、无进展生存期[MD = 2.12, 95%CI (1.64, 2.60), P < 0.00001]方面均高于单纯化疗组。结论：在III、IV期NSCLC的治疗中，卡瑞利珠单抗联合化疗的疗效优于单纯化疗组。

Abstract: Objective: To systematically evaluate the efficacy and safety of camrelizumab combined with chemotherapy for the treatment of Stage III and IV non-small cell lung cancer (NSCLC) using a meta-analysis approach. Methods: Databases including CNKI, Wanfang, China Biological Medicine Database, and PubMed were searched. Data were extracted and cross-checked. The risk of bias in randomized controlled trials was assessed using the Cochrane Risk of Bias Tool in RevMan5.4 software. Subsequently, a meta-analysis was performed using the same software. Results: Seven randomized controlled trials involving a total of 463 patients were included. The results of the meta-analysis showed that compared to chemotherapy alone, the combination of camrelizumab and chemotherapy significantly improved the objective response rate [OR = 3.04, 95%CI (1.90, 4.85), P < 0.00001] and progression-free survival [MD = 2.12, 95%CI (1.64, 2.60), P < 0.00001]. Conclusion: In the treatment of Stage III and IV NSCLC, camrelizumab in combination with chemotherapy demonstrates superior efficacy over chemotherapy alone.